Barr Ellison Solicitors – commercial property
Mid banner advertisement: BDO
ARM Innovation Hub
Advertisement: EY Mid banner
Advertisement: Simpsons Creative
Advertisement: Hewitsons mid banner
Advertisement: Kao Data Centre mid banner
RealVNC mid banner careers
Advertisement mid banner S-Tech 1
Advertisement: EBCam mid banner
Advertisement: Cambridge Network mid banner
Advertisement: Howard Group mid banner
Advertisement: Mogrify mid banner
Advertisement: RSM
Advertisement – Charles Stanley mid banner
18 January, 2021 - 11:07 By Tony Quested

LifeArc and Metrion extend neuroscience drug discovery collaboration

Metrion Biosciences, a Cambridge ion channel CRO and drug discovery company, and medical research charity LifeArc have extended a neuroscience drug discovery collaboration for a further 12 months as a result of the continued success of the partnership to date.

The collaboration is focused on the discovery of novel selective small molecular modulators of a specific two-pore domain potassium ion channel target, identified as likely to be involved in neurological pathogenesis, and has now progressed into the hit-to-lead optimisation phase.

Initially signed in January 2019, the collaboration agreement was extended for the first time in December 2019. Following the achievement of mutually agreed criteria LifeArc has now exercised the option to extend the programme for a further 12 months.

Metrion provides validated ion channel and electrophysiology-based assays and safety profiling services. LifeArc uses its expertise to identify novel modulators of CNS ion channel targets and all new chemical syntheses, with Metrion evaluating the pharmacological activities of LifeArc compounds using both automated electrophysiology and manual patch clamp technologies.

Dr Edward Stevens, head of Drug Discovery, Metrion Biosciences, said: “The continued success of our collaboration with LifeArc is testament to the strength of both teams and the long standing and successful research relationship between our companies.

“The transition to lead optimisation for key chemical series, along with continuation of selected hit-to-lead activities, is very exciting.”

Newsletter Subscription

Stay informed of the latest news and features